August 29, 2022

SAN RAMON, CALIF., AUGUST 29, 2022—CooperVision’s MiSight® 1 day myopia control contact lens was recently recognized in the German Design Council’s 2022 German Innovation Awards. In the field of Medical & Health, it received a special mention in “Excellence in Business to Consumer.”

“This award represents a tremendous sense of achievement and means a lot to us,” said Johannes Zupfer, General Manager of Germany, Austria and Switzerland at CooperVision. “On the one hand, it reflects our competence in terms of developing innovative contact lenses. But it also underscores our commitment to delivering solutions to our retail partners that will provide them with the best possible support in their day-to-day business.”

“Building a successful myopia management program is extremely important and the right thing to do, given the growing number of nearsighted children,” explained Zupfer. “Providing contact lenses early on, which slow down childhood myopia progression, reduces the risk of eye disease and can contribute to a child’s quality of life. That is and always has been our motivating force.”

The German Innovation Award is given for products, technologies, and services that break new ground in terms of innovation and for solutions that clearly stand out from conventional approaches. The distinction "Special Mention" is awarded to innovations distinguished for their well-conceived individual features, innovative approaches, or skillfully detailed solutions.

A daily disposable, dual-focus contact lens designed to slow myopia progression in children, MiSight® 1 day is available in more than 30 countries. It has received CE certification, as well as approval from the U.S. FDA* and Chinese NMPA. A seven-year, international study has shown that the lens works for nearly all children with myopia†1 and that the myopia control benefits are retained after treatment ends.‡2,3

“Myopia progression doesn’t wait, so myopia management can’t,” said Elizabeth Lumb, BSc (Hons) MCOptom, FBCLA, Director of Global Professional Affairs, Myopia Management, CooperVision. “We’re honored to have MiSight® 1 day’s innovation celebrated, and above all, we’re grateful that this recognition can aid in spreading the word about myopia and myopia management.”

# # #

*U.S. Indications for use: MiSight® 1 day (omafilcon A) soft (hydrophilic) contact lenses for daily wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters(spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal.

90% of myopic eyes respond to MiSight® 1 day treatment; ages 11-15 at start of wear, n=90.

12 months post-treatment, evidence indicates that no  accumulated myopia control benefits were lost following 3 or 6-years of MiSight® 1 day wear (on average, for children aged 8-15 at start of wear). Instead, eye growth reverted to expected, age average myopic progression rates.

About CooperVision
CooperVision, a division of CooperCompanies (NYSE:COO), is one of the world’s leading manufacturers of contact lenses. The company produces a full array of daily disposable, two-week and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges such as astigmatism, presbyopia, childhood myopia, and highly irregular corneas; and offers the most complete portfolio of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com.

About CooperCompanies
CooperCompanies ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE:COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, Calif., Cooper has a workforce of more than 12,000 with products sold in over 100 countries. For more information, please visit www.coopercos.com

Media Contact
Hannah Barry, Counselor, McDougall Communications
hannah@mcdougallpr.com or +1-585-645-8985


Chamberlain P et al. Long-Term Effect of Dual-Focus Contact Lenses on Myopia Progression in Children: A 6-year Multicenter Clinical Trial. Optom Vis Sci 2022 In Press.

Chamberlain P, Arumugam B, et al. Myopia progression on cessation of Dual-Focus contact lens wear: MiSight 1 day 7 year findings. Optom Vis Sci 2021;98:E-abstract 210049.

Hammond D, Arumugam B, et al. Myopia Control Treatment Gains are Retained after Termination of Dual-focus Contact Lens Wear with no Evidence of a Rebound Effect. Optom Vis Sci 2021;98:E-abstract 215130.